Table 4.
Comparison of clinical characteristics of patients who underwent AS according to diagnostic methods.
| AS after PBx | AS after TURP | P | |
|---|---|---|---|
| No. of patients | 83 | 39 | |
| Age (yr) | 69.1 ± 7.4 | 73.5 ± 8.5 | 0.022 |
| Charlson comorbidity index (≥2) | 6 (7.2) | 2 (5.1) | 0.663 |
| Family history | 1 (1.2) | 2 (5.1) | 0.194 |
| PSA (ng/mL) | 5.9 ± 3.0 | 4.3 ± 3.2 | 0.004 |
| Prostate volume (cc) | 45.6 ± 18.5 | 49.5 ± 20.0 | 0.249 |
| PSA density (ng/mL/cc) | 0.14 ± 0.08 | 0.09 ± 0.07 | <0.001 |
| Gleason Grade group | 0.126 | ||
| 1 | 76 (91.6) | 32 (82.1) | |
| 2 | 7 (8.4) | 7 (18.9) | |
| Clinical stage | 0.144 | ||
| cT1c | 60 (72.3) | ||
| cT1a | 30 (77.0) | ||
| cT1b | 3 (7.6) | ||
| cT2 | 23 (27.7) | 6 (15.4) | |
| No. of positive biopsy cores | <0.001 | ||
| 1 | 75 (90.4) | 3 (7.7) | |
| 2 | 8 (9.6) | 1 (2.6) | |
| Maximum percentage involvement | <0.001 | ||
| ≤50% | 81 (97.6) | 1 (2.6) | |
| >50% | 2 (2.4) | 1 (2.6) | |
| % of positive biopsy chips | 4.9 ± 6.2 | ||
| Risk stratification | 0.959 | ||
| Very low | 0 (0.0) | 0 (0.0) | |
| Low | 65 (78.3) | 28 (71.8) | |
| Favorable intermediate | 16 (19.3) | 10 (25.6) | |
| Unfavorable intermediate | 2 (2.4) | 1 (2.6) | |
| Follow-up duration (mo) | 41.3 (25.7–57.7) | 52.2 (29.1–84.3) | 0.047 |
| AS adherence duration (mo) | 28.5 (16.0–46.2) | 41.3 (27.9–71.6) | 0.001 |
| Termination of AS | 51 (61.4) | 19 (48.7) | >0.999 |
Data are n (%), mean ± standard deviation or median (interquartile range).
AS, active surveillance; PBx, prostate biopsy; PSA, Prostate-specific antigen; RP, radical prostatectomy; TURP, transurethral resection of prostate.